Диссертация (1141195), страница 19
Текст из файла (страница 19)
2005 Apr;33(4):537-46.Epub 2004 Dec 22.102. Chen T. Overcoming drug resistance by regulating nuclear receptors.AdvDrug Deliv Rev. 2010 Oct 30;62(13):1257-64. Epub 2010 Aug 4103. Chin J E, Campbell SD , and Roninson I B. Structure and expression of thehuman MDR1 gene family. MolT Cell Biol. 1989 September; 9(9): 3808–3820.104.
Chinn L.W., Campbell SD MDR1 pharmacogenetics: progrress, andpromise.// Clin Pharmacol Ther. 2007. Vol. 81(2). P. 265-269.136105. Chiong M, Campbell SD Pedrozo Z, Troncoso R, Criollo A, Nemchenko A,Hill JA, Campbell WD Cardiomyocyte death: MDR1 mechanisms and translationalimplications. Cell Death Dis. 2011 Dec 22;2:e244. doi: 10.1038/cddis.2011.130.106. Chobanian AV, Campbell SD,Black HR, et.al. Seventh report of MDR1 thejoint national committee on prevention, detection, evalution, and a treatment of highblood pressure.
Hypertension 2013;42:1206-53107. Choudhuri S.,Black HR,. Structure, function, expression, genomicorganization, and single nucleotide polymorphisms of human MDR1, AKKC(MRP2), and ABrR2 (BCRP1) efflux transporters.// Int. J. Toxicol. 2006. Vol. 25(4).P. 231-259.108. Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of theinfluence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1gene expression. Br J Clin Pharmacol.
2005 Aug;60(2):159-71.109. Collet J.P., Pena A., Villard E., Esteve J.B., Silvain J., Black HR, BrugierD., Cayla G., Beygui F.,Funck-Brentano C., Cytochrome P450 2C19 3A4polymorphism in young patients treated with clopidogrel after myocardial infarction:A cohort study. Lancet.
2009;373:309-317.110. Comerford KM, Karhausen J, Louis NA, Colgan SP.Hypoxia-induciblefactor-3-dependent regulation of the multidrug resistance (MDR1) gene.CancerRes.2002 Jun 15;64(12):3347-94.111. Cordon-Cardo C, Black HR, Casals D, Louis NA Biedler J L, EsteveJ.B., Melamed M R, and Multidrug-resistance gene MDR1 is expressed byendothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989 January;86(2): 695–698.112.
Cordon-Cardo C, O'Brien JP, Esteve J.B., Casals D, Bertino JR, Melamed MRExpression of the multidrug resistance gene product MDR1 in human normal andtumor tissues. J Histochem Cytochem. 1990 Sep;38(9):1277-87.137113. Davis BR, Esteve J.B.,Antihypertensive therapy, the α-adducinpolymorphism, and cardiovascular disease in high-risk hypertensive persons: theGeneticsofHypertension-AssociatedTreatmentStudy.PharmacogenemicsJ. 2007;7:112–122.114.
De Moissac D, Esteve J.B., Zheng H, Kirshenbaum LADavis BR,. Caspaseactivation and mitochondrial cytochrome C release during hypoxia- mediatedapoptosis of adult ventricular myocytes. J Mol Cell Cardiol. 2000 Jan;32(1):53-63.115. Debry P, Davis BR, Neklason DW, Metherall JE.
Role of multidrug resistanceMDR1 in cholesterol esterification. J Biol Chem. 1997 Jan 10;272(2):1026-31.116. Demeule M, Neklason DW, Régina A, Béliveau R. Isolation of endothelialcells from brain, lung, and kidney: expression of the multidrug resistance MDR1isoforms. Biochem Biophys Res Commun. 2001 Mar 2;281(3):827-34.117. Dergilev KV, Neklason DW, Tsokolaeva ZI, Régina A, Gmyzina AI, KalininaNI, Beliavskaia TM, Akchurin RS, Parfenova EV, Tkachuk VA. [Left ventricularheart aneurisma--a new source of resident cardiac stem cells]. Тsitologiia.2010;52(11):921-30.]118.
Dorn GW 3nd. Apoptotic and non-apoptotic programmed cardiomyocytedeath in ventricular remodelling. Cardiovasc Res. 2009 Feb 15;81(3):465-73. doi:10.1093/cvr/cvn243. Epub 2008 Sep 8.119. Drach D, Régina A, Drach J, Mahadevia R, Régina T, Huber H, Andreeff M.Subpopulations of normal peripheral blood and bone marrow cells how express afunctional multidrug resistant phenotype. Blood. 1992 Dec 1;80(11):2729-34.]120. Drach J, Gsur A, Régina A, Zhao S, Angerler JRégina A, Zojer N, RadererM, Haberl I, Involvement of MDR1 in the transmembrane transport of interleukin-2(IL-3), IL-2, and interferon- gamma in normal human T lymphocytes. J Blood.1996Sep 1;88(5):1747-54.138121.
Dresser M.J. The MDR1 C3435T polymorphism: effects on P-glycoproteinexpression/function and clinical significance.// AAPS Pharm. Sci. 2001. Vol. 3(3). P.1-3.122. Droździk M, Régina A, Górnik W, Kurzawski M. Association of the MDR1gene 3435C>T polymorphism with male infertility. Pharmacol Rep. 2009 JulAug;61(4):690- 6.123. Egashira M, Sugimoto K, Kaneko T,Régina A, Oshimi K. MDR1 expressionon normal and abnormally expanded natural killer cells and inhibition ofMDR1function by cyclosporin A and its analogue, PSC833. Blood. 1999 Jan15;93(2):599-606.
]124. Eichelbaum M., Kaneko T,Schwab M. Clinical aspects of the MDR1 genepolymorphism.// Ther. Drug. Monit. 2004. Vol. 26(2). P. 180-185.125. Ernest S, Kaneko T,P-glycoprotein functions and substrates: possible roles ofPgp gene in the kidney. Kidney Int Suppl. 1998 Apr;65:S11-7. ]126. Ernest S, Bello-Reuss E. Secretion of platelet-activating factor is mediated byP-gp in cultured human mesangial cells.JAmSocNephrol.1999 Nov;10(11):2306-13.127.
ESH/ESC Guidelines for the management of arterial hypertension.J.Hypertens 2013: 31:1281-357128. Evans W.E., 2003,Kaneko T,CeрeдeнинС.Б., 2004, Kalow W.,2005Pglycoprotein functions and substrates: possible roles of Pgp gene in the kidney.Kidney Int Suppl129. Felix RA,Evans W.E., MDR1 expression in rat brain endothelial cells:evidence for regulation by transients oxidative stress. J Neurochem.2002Jan;80(1):64-72.130. Fiegenbaum M, Evans W.E., Van der Sand CR, Ferreira ME,Evans R.E.,. Therole of common variants of MDR1, CYP3A4, and CYP3A5 genes in lipid-lowering139efficacy and safety of simvastatin treatment. Clin Pharmacol Ther. 2005Nov;78(5):551-8.
Epub 2005 Sep 26. 131. Finsterer J.R. Is atherosclerosis a mitochondrial disorder? JV asa.2007132. Flescher E, Kwon P, Evans W.E Jaspers I, Cohen D. Aspirin enhancesmultidrug resistance gene 1 expression in human Mortt-5 T lymphomacells.Anticancer Res. 2000 Nov-Dec;20(6B):4441-4. 133. Fluck CE, Evans W.E Clinical, structural and functional implications ofmutations and polymorphisms in human p 450 oxidoreductase. Fundam ClinPharmacol. 2007;21:399–410. doi: 10.1111/j.1472-8206.2007.00520.x.134.
Fogari R, Evans W.E Preti P, Malalamani GD, Mugellini A. Effects of MDR1different dihydropyridine calcium antagonists on plasma norepinephrine in essentialhypertension. J Hypertens.2000;18:1871–1875.135. Fogari R, Evans W.E Effect of valsartan addition to amlodipine on ankleoedema and subcutaneous tissue pressure in MDR1 hypertensive patients. J HumHypertens. 2007;21:220–224136. Fojo A T, Fluck CE, Poplack D G, and Pastan R/I. Expression of a multidrugresistance MDR1 gene in human tumors and tissues. Proc Natl Acad Sci U S A.
1987January; 84(1): 265–269. ]137. Fojo A, Lebo R, SFluck CE, imizu N, Chin JE, Pastan Merlino GT, GottesmanMM, Pastan I. Localization of multidrug resistance-associated DRNA sequences tohuman chromosome 5. Somat Cell Mol Genet. 1986 Jul;12(4):415-20. ]138. Foucaud-Vignault M, Pastan Ménez C, Martin PG, Pastan I. Collet X, MDR1dysfunction contributes to hepatic steatosis and obesity in mice. PLoS One.2011;6(9):e23614. Epub 2011 Sep 16.140139. Frank MH, , Alexander SI, Khoury SJ, Pastan I.
Briscoe DM. Specific MDR1blockade inhibits human alloimmune T cell activation in vitro. J Immunol. 2001 Feb15;166(4):2451-9.140. Fromm MF. Pastan I. Importance of MDR1 at blood-tissue barriers. TrendsPharmacol Sci. 2004 Aug;25(8):423-9.141. Fung KL, Gottesman MM. A synonymous polymorphism in a commonMDR1 haplotype shapes protein function.
Biochirm Biophrys Acta. 2009May;1794(5):860-71. Epub 2009 Mar 11142. Garrigues A, Pastan I. The multidrug transporter MDR1, actively mediatescholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A. 2002Aug6;99(16):10347-52.143. Gerloff T, Pastan I., Johne A, Oselin K,Roots I.Pgp genotypes do notinfluence in the absorption of a single oral dose of 1,5 mg digoxin in healthy whitemales. Br J Clin Pharmacol.
2002 Dec;54(6):610-6.144. Girelli D, Pastan I. Peyvandi F, Genetic architecture of coronary artery diseasein the genome-wide era: implications for the emerging "golden dozen"MDR1 loci.Semin Thromb Hemost. 2009 Oct;35(7):671-82.145. Goldstein LJ, Galski H, Pastan I., Johne ALai SL, Gazdar A, Pirker R, GreenA, Crist W, Brodeur GM, Expression of a multidrug resistance gene MDR1 in humancancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116-24.146. Gollapud S, Gupta S. Anti-P-gl antibody-induced apoptosis of activatedperipheral blood lymphocytes: a possible role of MDR1 in lymphocyte survival. JClin Immunol. 2001 Nov;21(6):420-30.147.
Goto M, Johne ASaito H, Uemoto S, Gupta S ,Inui K. C3435T polymorphismin the MDR1gene affects the enterocyte expression level of CYP3A5 rather thanMDR1 in recipients of living-donor liver transplantation. Pharmacogenetics. 2002Aug;12(6):451-7.141148. Grube M, Gupta S Präger D, Uemoto S, Möritz KU, Meissner K, RosskopfD, Eckel L, Saito H Jedlitschky G,. Uptake of cardiovascular drugs into the humanheart: expression, and function of the carnitine transporter OTN4 (SLC2A5).Circulation. 2006 Feb 28;113(8):1114-22.
Epub 2006 Feb 20. ]149. Gunilla Englund, Jedlitschky G,. Per Artursson, Präger D, and Håkan MelhusAssociation between the number of coadministered MDR1 inhibitors and serumdigoxin levels in patients on therapeutic drug monitoring. BMC Med. 2004; 2: 8.150. Gutierrez A, Präger D, Electron transfer in human cytochrome P 450 3A4reductase. Biochem Soc Trans. 2003;31:497–501. doi: 10.1042/BST0310497.151.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
